Actively Recruiting
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)
Led by Hui-Sheng Chen · Updated on 2025-08-21
30
Participants Needed
1
Research Sites
341 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In 2015, five randomized trials showed efficacy of endovascular thrombectomy over standard medical care in patients with acute ischemic stroke caused by occlusion of arteries of the proximal anterior circulation. However, sufficient recanalization (mTICI2b-3) can 't be acquired in all patients under thrombectomy. There is a lack of evidence that whether salvage intra-arterial thrombolysis is beneficial for patients with insufficient recanalization after endovascular thrombectomy. The EXTEND-IA TNK study indicated that tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset. This study intends to explore the proportion of sufficient recanalization (2b/3) after intra-arterial tenecteplase administration in patients undergoing thrombectomy with insufficient recanalization (1/2a).
CONDITIONS
Official Title
Improving Neuroprotective Strategy for Ischemic Stroke With Poor Recanalization After Thrombectomy by Intra-arterial TNK (INSIST-TNK)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Acute ischemic stroke with large vessel blockage in the anterior circulation
- Undergoing mechanical thrombectomy treatment
- Insufficient blood flow restoration (mTICI 1 or 2a) after thrombectomy
- Informed consent available
You will not qualify if you...
- Sufficient recanalization (TICI 2b-3)
- More than 3 thrombectomy device passes
- Hemorrhagic stroke including cerebral or subarachnoid hemorrhage
- Coagulation disorders, bleeding tendency, or platelet count below 100000/mm3
- Severe liver or kidney dysfunction or requiring dialysis
- Severe uncontrolled high blood pressure (systolic over 200 mmHg or diastolic over 110 mmHg)
- Allergy to study drugs
- Assessed as unsuitable for study participation by researchers
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
General Hospital of Northern Theater Command
Shenyang, China, 110840
Actively Recruiting
Research Team
Z
Zi-Ai Zhao, Doctor
CONTACT
L
Lin Tao, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here